The percentage of cells expressing these molecules appeared higher among CD8+ T cells in the more immunogenic MCA205, MC38, and CT26 mouse tumors relative to the poorly immunogenic B16 melanoma and also higher in human melanoma relative to NSCLC and RCC, potentially related to the immunogenic burden of somatic mutations typically associated with these tumor subtypes (Alexandrov et al., 2013). The gene discussed is CD8A; the disease is melanoma.